Lung Cancer Treatment Advances in 2022

Abstract

The therapeutic landscape of lung cancer treatment is changing rapidly, and new data was presented at the recently concluded American Society of Clinical Oncology 2022 (ASCO22) meeting. We highlight studies of clinical relevance that represent significant updates in the current management of non-small cell lung cancer (SCLC) and small cell lung cancer (NSCLC). We summarize the updates in early-stage NSCLC, mutated and non-mutated advanced NSCLC as well as small cell lung cancer (SCLC), and discuss these advances in the context of the current clinical standard of care.

Keywords:

• Early-stage lung cancer
• metastatic lung cancer
• non-small cell lung cancer
• Small cell lung cancer
• TKI
• oncogenes

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.